Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...

Friday was a doozy for many biotech and pharmaceutical companies after news broke late Thursday that President-elect Donald Trump would nominate vaccine skeptic Robert F. Kennedy Jr. to the nation's ...

Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to ...

Moderna’s ( NASDAQ: MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good ...

For young, healthy people who may be wondering, “do I need a COVID booster at all?”, having one annually is sensible.

Pfizer's stock dropped 4.3 percent while Moderna's fell 3.1 percent and Novavax saw a 2.8 percent dip in its stock Friday ...

( NewsNation) — Shares in some pharmaceutical and biotechnology companies, including those that manufacture vaccines, fell ...

The standout company among those yet to report is Nvidia Corp. (NVDA), which is scheduled to announce quarterly results on Wednesday.

If you missed the early fall push for flu and COVID-19 vaccines, it’s not too late. Health officials say it’s important to ...

Pharmaceutical industry representatives in Washington are scrambling to measure the damage Robert F. Kennedy Jr. might inflict on the FDA.

President-elect Donald Trump said he’s tapping Robert F. Kennedy Jr. to run the Department of Health and Human Services, a ...